COVID-19
Researchers are now concerned that the same health inequalities that have made certain racial and ethnic groups experience higher infection and death rates also drive disparities in treatment for long Covid.
The Infectious Disease Research Institute (IDRI), Duke Human Vaccine Institute, and 3M are working together on a potential vaccine that might protect individuals against multiple variants of SARS-CoV-2.
It was a busy week for clinical trial news. Here’s a look.
On Thursday, Pfizer Chief Executive Officer Albert Bourla who is “not at all” in favor of the U.S. position, stated that the real challenge is manufacturing capacity.
Six months after receiving Emergency Use Authorization from the U.S. FDA for COVID-19 vaccines, Pfizer/BioNTech and Moderna are planning to seek full approval for the preventative medications.
There’s a fair amount of new information coming out about COVID-19 and vaccines. Here’s a roundup of some of the top stories.
While the U.S. had been one of a few rich nations holding out – along with Canada, the European Union and Britain – on some level, Wednesday’s announcement of support for the proposal is not unexpected.
While mix-and-match sounds more like a meal deal at your local fast-food chain, it’s now the colloquial term being used for the approach currently under study in the U.K. for administering two doses of different types of COVID-19 vaccines.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
We interviewed Krissy Fuller, a human resources consultant, to learn more about the issue of mandated vaccines from an HR perspective and shared her predictions on what changes she thinks will last after the pandemic.
PRESS RELEASES